News
Altimmune mourns the passing of CFO Richard Eisenstadt
Altimune, Inc.
GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the company’s chief financial officer, passed away unexpectedly on Monday, June 24, 2024.
“We are all shocked and saddened by Rich’s passing. On behalf of everyone at Altimmune, I extend our sincerest condolences to his family during this difficult time,” said Vipin K. Garg, Ph.D., President and CEO of Altimmune. “Rich was not only a brilliant and dedicated leader, but a close friend who brought a sense of wit and joy to our workplace that will be sorely missed by all who had the privilege of working with him. His unique blend of hard work and humor, along with his immeasurable contributions to our Company, will continue to inspire us.”
Mr. Eisenstadt’s duties have been assumed and are being performed by Altimmune’s finance and accounting team until his replacement is named. The company has begun a search for his replacement.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative, next-generation peptide-based therapeutics. The company is developing pemvidutide, a dual GLP-1/glucagon receptor agonist for the treatment of obesity and MASH. For more information, visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Garg Vipin
President and CEO
Phone: 240-654-1450
ir@altimmune.com
Investor Contacts:
Lee Roth
McClellan Burns
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com
Media Contact:
Danielle Cantinho
Inizio Evoke, Biotechnology
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
